A cytomegalovirus vaccine for transplantation: Are we closer?

Journal of Infectious Diseases

Volumn 197, Issue 12, 2008, Pages 1631-1633

  Go, Vera ^a   Pollard, Richard B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE; GLYCOPROTEIN B; PHOSPHOPROTEIN; PHOSPHOPROTEIN 65; VCL CB01;

ANTIBODY RESPONSE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE ESCALATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INJECTION SITE PAIN; NOTE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; HUMANS; IMMUNOCOMPROMISED HOST; ORGAN TRANSPLANTATION;

EID: 46349110166     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/588386     Document Type: Note

References (27)

1. Zhang LJ, Hanff P, Rutherford C, Churchill WH, Crumpacker CS. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis 1995; 171:1002-6.
2. Collier AC, Meyers JD, Corey L, Murphy VL, Roberts PL, Handsfield HH. Cytomegalovirus infection in homosexual men: relationship to sexual practices, antibody to human immunodeficiency virus, and cell-mediated immunity. Am J Med 1987; 82:593-601.
3. Guinan ME, Thomas PA, Pinsky PF, et al. Heterosexual and homosexual patients with the acquired immunodeficiency syndrome: a comparison of surveillance, interview, and laboratory data. Ann Intern Med 1984; 100:213-8.
4. Crumpacker CS, Wadhwa S. Cytomegalovirus. In: Mandell GL, Bennett JE, Dolin R. Principles and practices of infectious diseases. 6th ed. Vol 2. Philadelphia, PA: Elsevier, 2005:1786-801.
5. Steininger C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin Microbiol Infect 2007; 13:953-63.
6. Stratton K, Durch J, Lawrence R. Vaccines for the 21st century: a tool for decision making. Vol 1. Washington, DC. National Academy Press, 2001:476.
7. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:673-85.
8. Garnadia LE, Remmerswaal EB, Weel JF, Bernelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-γ-producing DC4+ T cells in protection against CMV disease. Blood 2003; 101:2686-92.
9. Kern F, Bunde T, Faulhaber N, et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002; 185:1709-16.
10. Adler SP. Human CMV vaccine trials: what if CMV caused a rash? J Clin Virol 2008; 41:231-6.
11. Reap EA, Dryga SA, Morris J, et al. Cellular and humoral immune response to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1 and gB proteins. Clin Vaccine Immunol 2007; 14:748-55.
12. Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995; 171:26-32.
13. Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. Ann Intern Med 1991; 114:525-31.
14. Balfour HH, Welo PK, Sachs GW. Cytomegalovirus vaccine trial in 400 renal transplant candidates. Transplant Proc 1985; 17:81-3.
15. Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant patients. Transplantation 1994; 58:1176-8.
16. Heineman TC, Schleiss M, Bernstein DI, et al. A phase I study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 2006; 193:1350-60.
17. Marshall BC, Adler SP. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59). Viral Immunol 2003; 16:491-500.
18. Adler SP, Plotkin SA, Gonczol E, et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody response to a live attenuated CMV vaccine (Towne). J Infect Dis 1999; 180:843-6.
19. Bernstein DI, Schleiss MR, Berencsi K, et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 2002; 185:686-90.
20. Selinsky C, Luke C, Wloch M, et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Human Vaccines 2005; 1:16-23.
21. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv Genet 2005; 55:25-40.
22. Doh SG, Vahlsing HL, Hartikka J, Liang X, Manthorpe M. Spatial-temporal patterns of gene expression in mouse skeletal muscle after injection of lacZ plasmid DNA. Gene Ther 1997; 4:648-63.
23. Wloch MK, Smith LR, Boutsaboualoy S, et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008; 197:1634-42 (in this issue).
24. Vilalta A, Mahajan RK, Hartikka J, et al. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum Gene Ther 2005; 16:1143-50.
25. Jacobson MA, Sinclair E, Bredt B, et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine 2006; 24:5311-19.
26. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloblative compared with myeloblative allogeneic stem cell transplantation: a matched control study. Blood 2002; 99:1978-85.
27. Sester M, Gärtner BC, Sester U, Grindt M, Mueller-Lantzsch N, Köhler H. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation 2003; 76:1229-30.